BE2014C027I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C027I2
BE2014C027I2 BE2014C027C BE2014C027C BE2014C027I2 BE 2014C027 I2 BE2014C027 I2 BE 2014C027I2 BE 2014C027 C BE2014C027 C BE 2014C027C BE 2014C027 C BE2014C027 C BE 2014C027C BE 2014C027 I2 BE2014C027 I2 BE 2014C027I2
Authority
BE
Belgium
Application number
BE2014C027C
Other languages
Dutch (nl)
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34115515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C027(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BE2014C027I2 publication Critical patent/BE2014C027I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2014C027C 2003-08-01 2014-04-29 BE2014C027I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49153403P 2003-08-01 2003-08-01
PCT/JP2004/011312 WO2005012326A1 (en) 2003-08-01 2004-07-30 Novel compounds having inhibitory activity against sodium-dependant transporter

Publications (1)

Publication Number Publication Date
BE2014C027I2 true BE2014C027I2 (en) 2023-12-14

Family

ID=34115515

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C027C BE2014C027I2 (en) 2003-08-01 2014-04-29

Country Status (36)

Country Link
US (3) US7943788B2 (en)
EP (4) EP1651658B2 (en)
JP (2) JP4130466B2 (en)
KR (2) KR100942622B1 (en)
CN (4) CN103214471B (en)
AR (1) AR045173A1 (en)
AU (1) AU2004260761B2 (en)
BE (1) BE2014C027I2 (en)
BR (1) BRPI0413232B8 (en)
CA (1) CA2534024C (en)
CR (2) CR8188A (en)
CY (3) CY1113813T1 (en)
DK (2) DK1651658T4 (en)
EA (2) EA015104B1 (en)
ES (4) ES2844401T3 (en)
FR (1) FR14C0034I2 (en)
HR (2) HRP20130124T4 (en)
HU (2) HUE037320T2 (en)
IL (2) IL173050A (en)
LT (1) LT2896397T (en)
LU (1) LU92426I2 (en)
ME (1) ME00411B (en)
MX (1) MXPA06001274A (en)
MY (1) MY143203A (en)
NL (1) NL300670I2 (en)
NO (3) NO333933B1 (en)
NZ (2) NZ545304A (en)
PL (2) PL1651658T5 (en)
PT (2) PT2896397T (en)
RS (1) RS53365B (en)
SG (1) SG145694A1 (en)
SI (2) SI1651658T2 (en)
TW (2) TWI365190B (en)
UA (1) UA83243C2 (en)
WO (1) WO2005012326A1 (en)
ZA (5) ZA200601685B (en)

Families Citing this family (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (en) * 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 Fastening element
ES2567571T3 (en) 2003-03-14 2016-04-25 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
LT2896397T (en) † 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
AU2005219779B2 (en) * 2004-03-04 2011-04-14 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
ATE557013T1 (en) 2004-03-16 2012-05-15 Boehringer Ingelheim Int GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THEIR PRODUCTION
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1773800A1 (en) * 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
US20080139484A1 (en) * 2004-09-29 2008-06-12 Kissei Pharmaceutical Co., Ltd. 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof
CA2587639A1 (en) 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP4496174B2 (en) * 2005-01-31 2010-07-07 田辺三菱製薬株式会社 Pharmaceutical composition
TWI365186B (en) * 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
AR053329A1 (en) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co INDOL DERIVATIVES USEFUL AS INHIBITORS OF GLUCOSE CONVEYORS DEPENDENT ON SODIUM (SGLT)
ATE445608T1 (en) 2005-02-23 2009-10-15 Boehringer Ingelheim Int GLUCOPYRANOSYL-SUBSTITUTED ((HETERO)ARYLETHYNYL-BENZYL)-BENZENE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTER TYPE 2 (SGLT2)
ATE453656T1 (en) 2005-04-15 2010-01-15 Boehringer Ingelheim Int GLUCOPYRANOSYL-SUBSTITUTED (HETEROARYLOXY-BENZYL)-BENZENE DERIVATIVES AS SGLT INHIBITORS
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (en) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
ES2346347T3 (en) 2005-07-27 2010-10-14 Boehringer Ingelheim International Gmbh DERIVATIVES OF ((HETERO) CICLOALQUILETINIL-BENCIL) -BENZENE AND ITS USE AS INHIBITORS OF THE SODIUM DEPENDENT GLUCOSE COTRANSPORTADOR (SGLT).
CA2620566A1 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200745075A (en) 2005-09-08 2007-12-16 Boehringer Ingelheim Int Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (en) * 2005-09-15 2007-09-26 Boehringer Ingelheim Int PROCEDURES TO PREPARE DERIVATIVES OF (ETINIL-BENCIL) -BENZENE REPLACED GLUCOPYRANOSIL AND INTERMEDIATE COMPOUNDS OF THE SAME
WO2007093610A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (en) 2006-05-03 2008-08-05 Boehringer Ingelheim Int BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
JP5230613B2 (en) * 2006-05-23 2013-07-10 テラコス・インコーポレイテッド Glucose transporter inhibitor and method of use thereof
TWI418556B (en) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp Indole derivatives
TWI432446B (en) * 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd Fused ring spiroketal derivative and use thereof as anti-diabetic drug
TWI403516B (en) * 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
US20080027014A1 (en) * 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
CA2664095A1 (en) * 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US20100093744A1 (en) 2006-10-13 2010-04-15 Chugai Seiyaku Kabushiki Kaisha Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UY30730A1 (en) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp CRYSTAL FORM OF HEMIHYDRATE 1- (B (BETA) -D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE
CN101611032B (en) * 2006-12-04 2012-07-18 詹森药业有限公司 Thienyl-containing glucopyranosyl derivatives as antidiabetic agents
KR101100072B1 (en) * 2006-12-21 2011-12-29 고토부키 세이야쿠 가부시키가이샤 Method for preparing C-glycoside derivatives and synthetic intermediates thereof
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
EP2112928A4 (en) * 2007-02-22 2014-01-08 Univ Utah Res Found SYNTHESIS OF NEW XYLOSIDES AND THEIR POTENTIAL USES
BRPI0809607A2 (en) * 2007-04-02 2014-09-30 Theracos Inc COMPOUND, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINATION, AND METHOD FOR TREATING A DISEASE
CN101679431B (en) * 2007-04-11 2013-08-14 Msd欧斯股份有限公司 Method for preparation of enantiomer of tetracyclic benzazepine
PE20090938A1 (en) 2007-08-16 2009-08-08 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL
MX2010002027A (en) * 2007-08-23 2010-03-15 Theracos Inc Benzylbenzene derivatives and methods of use.
MX2010002695A (en) * 2007-09-10 2010-04-01 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt.
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (en) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
ES2541141T3 (en) * 2008-01-31 2015-07-16 Astellas Pharma Inc. Pharmaceutical composition for the treatment of fatty liver diseases
AR070701A1 (en) * 2008-02-13 2010-04-28 Sanofi Aventis DERIVATIVES OF AROMATIC FLUOROGLYCOSIDS, MEDICINES THAT UNDERSTAND THESE COMPOUNDS AND USE OF THE SAME TO PRODUCE A MEDICINAL PRODUCT
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
MX2011001855A (en) * 2008-08-22 2011-03-24 Theracos Inc Processes for the preparation of sglt2 inhibitors.
MY155418A (en) 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2010031820A1 (en) * 2008-09-19 2010-03-25 Novartis Ag Glucoside derivatives and uses thereof as sglt inhibitors
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
BRPI1008560B1 (en) 2009-02-13 2021-08-31 Boehringer Ingelheim International Gmbh PHARMACEUTICAL COMPOSITION INCLUDING A SGLT2 INHIBITOR, A DPP-IV INHIBITOR AND OPTIONALLY ANOTHER ANTI-DIABETIC AGENT AND USES THEREOF
AP2011005795A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
CN101830876A (en) * 2009-03-12 2010-09-15 上海恒瑞医药有限公司 C-aryl glucoside derivative, preparation method thereof and application thereof in medicine
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101532412B1 (en) 2009-07-10 2015-06-29 얀센 파마슈티카 엔.브이. Crystallization method of 1- (β-D-glucopyranosyl) -4-methyl-3- (5- (4-fluorophenyl) -2-thienylmethyl) benzene
AU2010295722B2 (en) 2009-09-15 2015-04-16 Janssen Pharmaceutica, N.V. Use of alpha-methylglucoside (AMG) as an indicator for glucose absorption and excretion
AU2010303123B2 (en) 2009-09-30 2014-02-27 Boehringer Ingelheim International Gmbh Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene
JP5758900B2 (en) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Process for the preparation of glucopyranosyl-substituted benzylbenzene derivatives
UY32919A (en) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses
SI2488515T1 (en) 2009-10-14 2017-04-26 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EA021983B1 (en) 2009-11-02 2015-10-30 Пфайзер Инк. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
CN102115468B (en) * 2009-12-31 2014-06-11 上海特化医药科技有限公司 Synthesis method of 2, 5-disubstituted thiophene compound
CN102134226B (en) * 2010-01-26 2013-06-12 天津药物研究院 Phenyl C-glucoside derivatives, preparation method and use thereof
EP2552442A1 (en) 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
AU2011237775A1 (en) 2010-04-06 2012-11-22 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
TWI599360B (en) 2010-05-11 2017-09-21 健生藥品公司 Pharmaceutical formulations
JP5596799B2 (en) * 2010-05-11 2014-09-24 田辺三菱製薬株式会社 Canagliflozin-containing tablets
US8217183B2 (en) 2010-05-18 2012-07-10 Corning Incorporated Methods of making fused thiophenes
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2590631B1 (en) 2010-07-06 2016-10-26 Janssen Pharmaceutica NV Formulation for co-therapy treatment of diabetes
CN102372722A (en) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-aryl glucoside derivative, preparation method thereof and application of C-aryl glucoside derivative in medicine
WO2012033390A2 (en) * 2010-09-10 2012-03-15 Green Cross Corporation Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (en) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-aryl glucoside derivative, preparation method and application thereof
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102643256B (en) 2011-02-18 2014-12-24 上海璎黎科技有限公司 A kind of aryl glycoside compound and its preparation method and application
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
RS55056B1 (en) 2011-04-13 2016-12-30 Janssen Pharmaceutica Nv PROCESS FOR PREPARING UNITS USEFUL AS SGLT2 INHIBITORS
WO2012139495A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
KR20140019834A (en) * 2011-04-14 2014-02-17 노파르티스 아게 Glycoside derivatives and uses thereof
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
TWI542596B (en) * 2011-05-09 2016-07-21 健生藥品公司 (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxyl L-proline and citric acid cocrystals of methyl)tetrahydro-2H-piperan-3,4,5-triol
EP2712359B1 (en) 2011-05-20 2017-06-21 Janssen Pharmaceutica NV Process for the preparation of compounds useful as inhibitors of sglt-2
JP2014516038A (en) * 2011-05-20 2014-07-07 ヤンセン ファーマシューティカ エヌ．ベー． Process for the preparation of compounds useful as inhibitors of SGLT-2
WO2012165914A2 (en) * 2011-06-01 2012-12-06 Green Cross Corporation Novel diphenylmethane derivatives as sglt2 inhibitors
BR112013031032A2 (en) 2011-06-03 2016-11-29 Boehringer Ingelheim Int sglt-2 inhibitors for the treatment of metabolic disorders in patients treated with neuroleptic agents
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102827122B (en) * 2011-06-17 2015-01-14 山东轩竹医药科技有限公司 Glucoside derivate
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013061105A2 (en) * 2011-10-28 2013-05-02 Debreceni Egyetem Glycogen phosphorylase inhibitors
WO2013090550A1 (en) * 2011-12-15 2013-06-20 National Health Research Institutes Novel glycoside compounds
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
CN103570671B (en) * 2012-09-26 2016-03-30 上海天慈生物谷生物工程有限公司 A kind of hypoglycemic compound and method for making thereof and application
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EP2933250B1 (en) 2012-12-17 2017-08-09 Tianjin Institute Of Pharmaceutical Research Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof
CN103910769B (en) 2012-12-31 2018-10-02 上海璎黎药业有限公司 The compound of glucosan derivative and proline, crystal, preparation method and application
JP6173427B2 (en) * 2013-02-26 2017-08-02 田辺三菱製薬株式会社 Method for producing α-halotetraacylglucose
EP2968258B1 (en) * 2013-03-11 2020-02-12 Janssen Pharmaceutica NV Dual sglt1/sglt2 inhibitors
EP2968375B1 (en) 2013-03-14 2019-06-12 MSD International GmbH Methods for preparing sglt2 inhibitors
WO2014149789A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Combination of canagliflozin and probenecid for the treament of hyperuricemia
DK2981269T3 (en) 2013-04-04 2023-10-23 Boehringer Ingelheim Vetmedica Gmbh TREATMENT OF METABOLISM DISORDERS IN HORSES
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (en) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh THERAPEUTIC USES OF EMPAGLIFLOZINE
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
FI4000608T3 (en) 2013-04-18 2026-01-21 Boehringer Ingelheim Int Pharmaceutical composition, methods for treating and uses thereof
CA2911261A1 (en) 2013-05-08 2014-11-13 Lek Pharmaceuticals D.D. Novel crystalline hydrates of 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
WO2014195966A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited Amorphous form of canagliflozin and process for preparing thereof
CN104418834B (en) * 2013-08-23 2017-09-15 重庆博腾制药科技股份有限公司 A kind of synthetic method of antidiabetic medicine intermediate
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
CN104557894A (en) * 2013-10-18 2015-04-29 上海信谊药厂有限公司 Canagliptin crystal form and preparation method thereof
MX376097B (en) 2013-12-17 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in feline animals
CA2932674C (en) 2014-01-23 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
MX2016010011A (en) 2014-01-31 2016-10-07 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders.
EP2918579A1 (en) 2014-03-14 2015-09-16 LEK Pharmaceuticals d.d. Synthesis of 2-arylmethyl-5-aryl-thiophene
WO2015139386A1 (en) 2014-03-19 2015-09-24 杭州普晒医药科技有限公司 Canagliflozin monohydrate and crystal form thereof, preparation method and use thereof
CN103936725B (en) * 2014-04-01 2016-07-27 天津大学 The C crystal form of canagliflozin and crystallization preparation method thereof
FI3721882T3 (en) 2014-04-01 2024-09-24 Boehringer Ingelheim Vetmedica Gmbh Treatment of pituitary pars intermedia dysfunction in equine animals
CN105001213B (en) 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-aryl glycoside derivative, pharmaceutical composition, preparation method and application thereof
CN103980263B (en) * 2014-04-17 2016-08-03 海门瑞一医药科技有限公司 The synthesis technique of canagliflozin
EP2933255A1 (en) 2014-04-17 2015-10-21 LEK Pharmaceuticals d.d. Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
CN103936800A (en) * 2014-05-08 2014-07-23 安徽联创药物化学有限公司 Preparation method of 1-(1-methoxy pyran glucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl] benzene
TW201623321A (en) * 2014-05-13 2016-07-01 韓美藥品股份有限公司 Bicyclic derivatives and pharmaceutical composition including the same
EP2947077A1 (en) 2014-05-19 2015-11-25 LEK Pharmaceuticals d.d. Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides
EP3148979B1 (en) * 2014-05-27 2019-02-06 Glenmark Pharmaceuticals Limited Process for preparation of canagliflozin
CN105319294B (en) * 2014-06-20 2021-03-30 重庆医药工业研究院有限责任公司 Method for separating and determining canagliflozin and related substances thereof
US20160002275A1 (en) * 2014-07-03 2016-01-07 Cadila Healthcare Limited Process for preparation and purification of canagliflozin
CN104119324B (en) * 2014-07-23 2016-03-30 齐鲁天和惠世制药有限公司 A kind of preparation method of canagliflozin
CN104109157B (en) * 2014-08-04 2016-05-25 山东康美乐医药科技有限公司 The preparation method that Ka Gelie is clean
EP2990029A1 (en) 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
WO2016035042A1 (en) 2014-09-05 2016-03-10 Mylan Laboratories Ltd Process for the preparation of canagliflozin
CN104292209A (en) * 2014-09-11 2015-01-21 浙江丽晶化学有限公司 Novel method for preparing 2-(4-fluorophenyl) thiophene (compound V)
CZ2014634A3 (en) 2014-09-16 2016-03-23 Zentiva, K.S. Canagliflozin and cyclodextrin complexes
EP4403230A3 (en) 2014-09-25 2025-01-08 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
CN104817554A (en) * 2014-11-10 2015-08-05 镇江新元素医药科技有限公司 Glucoside derivatives and pharmaceutical compositions thereof
CN104478969A (en) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 O-galactoside derivative with alcoxyl phenyl group thiazolyl and preparation method and application thereof
CN104447906A (en) * 2015-01-14 2015-03-25 佛山市赛维斯医药科技有限公司 Alcoxyl phenyl group diosgenin-diglucoside derivative and preparation method and application thereof
CN104447905A (en) * 2015-01-14 2015-03-25 佛山市赛维斯医药科技有限公司 Derivative containing nitrobenzene and bis-O-glucoside and preparation method and application of derivative
CN104478968A (en) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 O-galactoside derivative with thiazolyl and preparation method and application thereof
CN104447907A (en) * 2015-01-14 2015-03-25 佛山市赛维斯医药科技有限公司 Compound containing nitro biphenyl diosgenin-diglucoside structure and preparation method and application thereof
CN104478962A (en) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 Class of halogenated phenyl group S-glucoside derivative and preparation method and application of class of halogenated phenyl group S-glucoside derivative
WO2016128995A1 (en) 2015-02-09 2016-08-18 Indoco Remedies Limited Process for the preparation of sglt inhibitor compounds
CN105884755B (en) * 2015-02-14 2019-05-28 正大天晴药业集团股份有限公司 Deuterium-modified carbon glycoside derivatives
US10308871B2 (en) 2015-02-19 2019-06-04 Jnc Corporation Liquid crystal compound having benzothiophene, liquid crystal composition and liquid crystal display device
EP3262039A4 (en) * 2015-02-27 2018-11-14 MSN Laboratories Private Limited Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof
CN104803977A (en) * 2015-03-03 2015-07-29 佛山市赛维斯医药科技有限公司 PTP1B derivatives containing tetrazole structures as well as preparation methods and applications of derivatives
WO2016142950A1 (en) * 2015-03-11 2016-09-15 Harman Finochem Limited A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form
WO2016191173A1 (en) 2015-05-22 2016-12-01 Janssen Pharmaceutica Nv Anhydrous crystalline form of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol
CN104926803B (en) * 2015-06-17 2017-12-22 南通常佑药业科技有限公司 A kind of preparation method of new SGLT2 inhibitor medicine
CZ2015435A3 (en) 2015-06-25 2017-01-04 Zentiva, K.S. Amorphous canagliflozin solid forms
CN104987320A (en) * 2015-08-03 2015-10-21 沧州那瑞化学科技有限公司 Preparation method of canagliflozin intermediates
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
ES2896101T3 (en) 2015-09-15 2022-02-23 Laurus Labs Ltd SGLT2 inhibitor co-crystals, process for their preparation and pharmaceutical compositions thereof
US10370365B2 (en) 2015-09-16 2019-08-06 Optimus Drugs (P) Limited Process for the preparation of Canagliflozin
WO2017046655A1 (en) * 2015-09-16 2017-03-23 Optimus Drugs (P) Ltd A novel process for the preparation of canagliflozin
CZ2015729A3 (en) 2015-10-13 2017-04-26 Zentiva, K.S. Preparation of intermediates for the synthesis of Canagliflozin and Dapagliflozin
WO2017064679A1 (en) * 2015-10-15 2017-04-20 Lupin Limited Process for the preparation of amorphous canagliflozin
CN105503845A (en) * 2015-12-01 2016-04-20 北京普德康利医药科技发展有限公司 Defluorinated canagliflozin compound, and preparation method and application thereof
WO2017093949A1 (en) * 2015-12-04 2017-06-08 Dr. Reddy's Laboratories Limited Substantially pure canagliflozin
CN106892929B (en) * 2015-12-17 2020-01-14 上海艾力斯医药科技有限公司 Spiroketal derivative and preparation method and application thereof
JP6851379B2 (en) 2015-12-21 2021-03-31 ヤンセン ファーマシューティカ エヌ．ベー． Crystallization procedure to obtain canagliflozin hemihydrate crystals
CN105541815B (en) * 2015-12-24 2018-07-13 寿光富康制药有限公司 A kind of preparation method of canagliflozin
WO2017141202A1 (en) 2016-02-17 2017-08-24 Lupin Limited Complex of sglt2 inhibitor and process for preparation thereof
MX392177B (en) * 2016-06-17 2025-03-19 Daewoong Pharmaceutical Co Ltd Method for producing diphenylmethane derivative
WO2018020506A1 (en) 2016-07-25 2018-02-01 Natco Pharma Ltd Process for the preparation of amorphous form of canagliflozin
BR112019005930A2 (en) 2016-10-19 2019-06-11 Boehringer Ingelheim Int combinations comprising a ssao / vap-1 inhibitor and a sglt2 inhibitor, and uses thereof
KR20250097990A (en) 2016-11-10 2025-06-30 베링거 인겔하임 인터내셔날 게엠베하 Pharmaceutical composition, methods for treating and uses thereof
CN106588898A (en) 2017-02-20 2017-04-26 浙江华海药业股份有限公司 Preparation method for amorphous form of canagliflozin
US11198703B2 (en) 2017-05-09 2021-12-14 Piramal Enterprises Limited Process for the preparation of SGLT2 inhibitors and intermediates thereof
TWI835735B (en) 2017-06-12 2024-03-21 比利時商健生藥品公司 Methods for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
CN108017612B (en) * 2017-11-29 2020-06-09 南通常佑药业科技有限公司 Preparation method of canagliflozin intermediate
KR20260037123A (en) 2017-11-30 2026-03-17 이도르시아 파마슈티컬스 리미티드 Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
BR112021000139A2 (en) 2018-07-19 2021-04-06 Astrazeneca Ab METHODS OF TREATMENT OF HFPEF USING DAPAGLIFLOZINE AND COMPOSITIONS UNDERSTANDING THE SAME
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2020050361A1 (en) * 2018-09-06 2020-03-12 株式会社トクヤマ PRODUCTION METHOD FOR β-C-ARYL GLYCOSIDE DERIVATIVE
DK3873600T5 (en) 2018-10-29 2024-03-18 Boehringer Ingelheim Int PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2020095010A1 (en) 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
TW202103709A (en) 2019-03-26 2021-02-01 比利時商健生藥品公司 Methods for treating subjects with chronic kidney disease
EP4064854A1 (en) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors in the drying-off of non-human mammals
CN110981851A (en) * 2019-12-24 2020-04-10 艾希尔（深圳）药物研发有限公司 Preparation method of canagliflozin impurity
JP7423800B2 (en) 2020-02-17 2024-01-29 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Use of SGLT-2 inhibitors for the prevention and/or treatment of heart disease in cats
EP4138826A1 (en) 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
TW202220672A (en) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 Methods of treating chronic kidney disease with dapagliflozin
AU2021202643B2 (en) 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
CN112159400B (en) * 2020-09-30 2026-01-09 天地恒一制药股份有限公司 A method for preparing and applying the α-isomer of canagliflozin
EP4315350A1 (en) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
CN113429379A (en) * 2021-06-28 2021-09-24 江苏法安德医药科技有限公司 LH-1801 intermediate and preparation method and application thereof
US20240269105A1 (en) 2021-07-28 2024-08-15 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN117715639A (en) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Use of SGLT-2 inhibitors for the prevention and/or treatment of kidney disease in non-human mammals
MX2024001184A (en) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines.
AU2022425078A1 (en) 2021-12-30 2024-08-08 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
JP2026508912A (en) 2023-03-06 2026-03-13 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー A system for delivering liquid pharmaceutical compositions, particularly liquid pharmaceutical compositions containing one or more SGLT-2 inhibitors.
WO2024226537A1 (en) 2023-04-24 2024-10-31 Newamsterdam Pharma B.V. Amorphous obicetrapib and sglt2 inhibitor combination
TW202508593A (en) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
CN121175053A (en) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 Combination treatment and/or prevention of kidney disease and/or hypertension in a non-human mammal comprising one or more SGLT-2 inhibitors and telmisartan
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension
WO2025160910A1 (en) * 2024-02-01 2025-08-07 New Wish Biotechnology Wuxi Co., Ltd. Indazole compound and pharmaceutical composition, preparation method and use thereof
WO2025224069A1 (en) 2024-04-23 2025-10-30 Bayer Aktiengesellschaft Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1476537A (en) * 1965-05-10 1967-04-14 Chimetron Sarl Glucosides derived from benzimidazole
US4160861A (en) * 1977-10-03 1979-07-10 Merck & Co., Inc. Method for the separation of antibiotic macrolides
US4584369A (en) * 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
JP2544609B2 (en) 1986-10-07 1996-10-16 和光純薬工業株式会社 TCNQ complex
CA1334969C (en) 1988-08-19 1995-03-28 Mark James Suto Substituted dihydroisoquinoline and phthalazine derivatives as potentiators of the lethal effects of radiation and certain chemotherapeutic agents, selected compounds, analogs andprocess
HU203896B (en) 1988-10-26 1991-10-28 Biogal Gyogyszergyar Process for producing glycosides of aromatic amines
JPH04253974A (en) 1991-02-05 1992-09-09 Ishihara Sangyo Kaisha Ltd Sulfonylurea compound, its production and herbicide containing the same
US5149838A (en) * 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
GB9208161D0 (en) 1992-04-14 1992-05-27 Pfizer Ltd Indoles
US5334225A (en) 1992-07-15 1994-08-02 Kao Corporation Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US6297363B1 (en) * 1993-02-12 2001-10-02 Nomura Co., Ltd. Glycoside indoles
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
CA2236007A1 (en) 1995-10-31 1997-07-17 Gerald Floyd Smith Antithrombotic diamines
JP3059088B2 (en) * 1995-11-07 2000-07-04 田辺製薬株式会社 Propiophenone derivatives and their production
JPH09263549A (en) 1996-01-25 1997-10-07 Fujisawa Pharmaceut Co Ltd Production of benzene derivative
AU719726B2 (en) * 1996-12-26 2000-05-18 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JPH10324632A (en) 1997-03-25 1998-12-08 Takeda Chem Ind Ltd Pharmaceutical composition
JP2000034239A (en) 1998-07-16 2000-02-02 Asahi Glass Co Ltd Method for producing trifluoromethylated aromatic compound
JP3857429B2 (en) 1998-07-17 2006-12-13 ポーラ化成工業株式会社 Sulfur-containing antifungal agent
US20020032164A1 (en) * 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4456768B2 (en) 2000-02-02 2010-04-28 壽製薬株式会社 Drug containing C-glycoside
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
AU2001232175B2 (en) 2000-03-03 2005-07-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
ES2254376T3 (en) * 2000-03-17 2006-06-16 Kissei Pharmaceutical Co., Ltd. GLUCOPIRANOSILOXIBENCILBENCENO DERIVATIVES, MEDICINAL PREPARATIONS CONTAINING THEM AND INTERMEDIARIES FOR THE PREPARATION OF DERIVATIVE INDICATES.
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
ATE455785T1 (en) 2000-11-02 2010-02-15 Ajinomoto Kk NEW PYRAZOLE DERIVATIVES AND AGENTS AGAINST DIABETES CONTAINING THEM
US6476352B2 (en) * 2000-12-18 2002-11-05 General Electric Company Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor
PL209375B1 (en) 2000-12-28 2011-08-31 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives and use thereof in medicines
CA2438593C (en) * 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
CA2438595C (en) 2001-02-27 2011-08-09 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
WO2002070020A2 (en) 2001-03-02 2002-09-12 University Of Western Ontario Polymer precursors of radiolabeled compounds, and methods of making and using the same
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2002083066A2 (en) * 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
JP4292570B2 (en) 2001-04-27 2009-07-08 味の素株式会社 N-substituted pyrazole-O-glycoside derivatives and therapeutic agents for diabetes containing them
GB0112122D0 (en) 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
US7271153B2 (en) 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
JP4115105B2 (en) 2001-07-02 2008-07-09 協和醗酵工業株式会社 Pyrazole derivative
WO2003011880A1 (en) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Glucopyrano syloxybenzyl benzene derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
US20030087843A1 (en) * 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
DE60208809T2 (en) * 2001-10-24 2006-11-02 Michael Warrington Burton Enzyme substrates for detecting β-D-ribofuranosidase activity
NZ552216A (en) 2001-11-16 2008-07-31 Bioform Medical Inc Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
US6617313B1 (en) * 2002-03-13 2003-09-09 Council Of Scientific And Industrial Research Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
US7417050B2 (en) 2002-04-18 2008-08-26 Astrazeneca Ab Heterocyclic compounds
DE10230605A1 (en) 2002-07-08 2004-01-29 Bayer Ag Substituted imidazotriazines
DE10231370B4 (en) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophene glycoside derivatives, medicaments containing these compounds and methods of making these medicaments
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
RU2322449C2 (en) 2002-08-09 2008-04-20 Тайсо Фармасьютикал Ко., Лтд. DERIVATIVES OF ARYL-5-THIO-β-D-GLYCOPYRANOSIDE AND THERAPEUTIC AGENT COMPRISING THEREOF USED IN DIABETES MELLITUS
JP4606876B2 (en) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 Pyrazole derivative, pharmaceutical composition containing the same, and pharmaceutical use thereof
DE10258008B4 (en) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclic fluoroglycoside derivatives, medicaments containing these compounds and methods of making these medicaments
DE10258007B4 (en) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatic fluoroglycoside derivatives, medicaments containing these compounds and methods for the preparation of these medicaments
BR0317929A (en) 2003-01-03 2006-04-11 Bristol Myers Squibb Co methods of producing c-aryl glycoside sglt2 inhibitors
ES2567571T3 (en) * 2003-03-14 2016-04-25 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
JP2004300102A (en) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd Condensed heterocyclic derivative, pharmaceutical composition containing the same and its pharmaceutical application
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
EP1637539B1 (en) 2003-06-20 2012-01-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
LT2896397T (en) † 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
RS20060320A (en) * 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Substituted indazole-o-glucosides
EP1679965A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES
EA010422B1 (en) * 2003-08-01 2008-08-29 Янссен Фармацевтика Н.В. Substituted indole-o-glucosides
UA86042C2 (en) * 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
TW200524951A (en) * 2003-08-01 2005-08-01 Janssen Pharmaceutica Nv Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides

Also Published As

Publication number Publication date
HRP20130124T4 (en) 2020-11-13
EP1651658A1 (en) 2006-05-03
DK1651658T3 (en) 2013-02-18
DK2896397T3 (en) 2017-11-06
HRP20130124T1 (en) 2013-04-30
ES2402098T5 (en) 2021-06-09
ZA200603879B (en) 2010-01-27
SI2896397T1 (en) 2018-01-31
MXPA06001274A (en) 2006-04-11
FR14C0034I2 (en) 2014-11-14
NO20060220L (en) 2006-05-02
SI2896397T2 (en) 2020-12-31
EA200800924A1 (en) 2008-08-29
ME00411B (en) 2011-10-10
LU92426I2 (en) 2014-06-10
ES2649737T5 (en) 2021-07-07
PL1651658T5 (en) 2020-11-30
ES2402098T3 (en) 2013-04-26
IL173050A0 (en) 2006-06-11
US8222219B2 (en) 2012-07-17
TWI365190B (en) 2012-06-01
BRPI0413232B8 (en) 2021-05-25
TWI385177B (en) 2013-02-11
RS20060079A (en) 2008-04-04
NO2014009I1 (en) 2014-06-02
DK1651658T4 (en) 2020-11-09
NL300670I2 (en) 2016-09-22
CN103819465A (en) 2014-05-28
CN1829729A (en) 2006-09-06
EP2896397A1 (en) 2015-07-22
TW201038588A (en) 2010-11-01
HRP20171838T4 (en) 2021-02-05
US8202984B2 (en) 2012-06-19
SI1651658T2 (en) 2020-12-31
CR11263A (en) 2010-05-19
JP2007518683A (en) 2007-07-12
CN104109155A (en) 2014-10-22
US20110105424A1 (en) 2011-05-05
NO20120585L (en) 2006-05-02
AR045173A1 (en) 2005-10-19
KR100778988B1 (en) 2007-11-28
CA2534024A1 (en) 2005-02-10
AU2004260761A1 (en) 2005-02-10
ES2649737T3 (en) 2018-01-15
KR100942622B1 (en) 2010-02-17
CR8188A (en) 2006-07-14
IL206831A (en) 2012-06-28
ZA200601685B (en) 2007-05-30
EP3251679B1 (en) 2020-12-16
IL206831A0 (en) 2011-08-01
EP2896397B2 (en) 2020-10-07
CY2014016I1 (en) 2015-12-09
NO334706B1 (en) 2014-05-12
PT2896397T (en) 2017-11-23
AU2004260761B2 (en) 2008-01-31
EP2514756B1 (en) 2014-12-17
FR14C0034I1 (en) 2014-06-13
TW200510441A (en) 2005-03-16
MEP61208A (en) 2011-05-10
JP4130466B2 (en) 2008-08-06
US20120058941A1 (en) 2012-03-08
EP2896397B1 (en) 2017-09-06
ZA200603882B (en) 2010-03-31
JP5065135B2 (en) 2012-10-31
EP1651658B1 (en) 2013-01-16
SI1651658T1 (en) 2013-04-30
CY1113813T1 (en) 2015-12-09
WO2005012326A1 (en) 2005-02-10
MY143203A (en) 2011-03-31
NZ575711A (en) 2010-05-28
KR20060057589A (en) 2006-05-26
US7943788B2 (en) 2011-05-17
PL2896397T3 (en) 2018-03-30
EP1651658B2 (en) 2020-08-12
HK1086277A1 (en) 2006-09-15
PL1651658T3 (en) 2013-05-31
IL173050A (en) 2011-06-30
NO333933B1 (en) 2013-10-28
BRPI0413232A (en) 2006-10-03
UA83243C2 (en) 2008-06-25
EA010299B1 (en) 2008-08-29
JP2008266328A (en) 2008-11-06
EA200600351A1 (en) 2006-08-25
EP2514756A1 (en) 2012-10-24
ZA200700550B (en) 2009-08-26
HUE037320T2 (en) 2018-08-28
CY1119814T1 (en) 2018-06-27
NO2014009I2 (en) 2016-08-01
ES2844401T3 (en) 2021-07-22
SG145694A1 (en) 2008-09-29
HRP20171838T1 (en) 2018-01-12
CA2534024C (en) 2009-06-02
ES2531660T3 (en) 2015-03-18
PT1651658E (en) 2013-03-07
EA015104B1 (en) 2011-06-30
NZ545304A (en) 2009-04-30
LU92426I9 (en) 2019-01-16
ZA200603881B (en) 2010-01-27
US20050233988A1 (en) 2005-10-20
KR20070065454A (en) 2007-06-22
DK2896397T4 (en) 2020-11-16
RS53365B (en) 2014-10-31
BRPI0413232B1 (en) 2018-03-06
PL2896397T5 (en) 2023-06-19
LT2896397T (en) 2017-11-27
CN103214471B (en) 2018-02-06
HUS1400021I1 (en) 2016-08-29
EP3251679A1 (en) 2017-12-06
CY2014016I2 (en) 2015-12-09
CN103214471A (en) 2013-07-24

Similar Documents

Publication Publication Date Title
BE2014C027I2 (en)
FR13C0068I1 (en)
BE2013C067I2 (en)
BE2013C038I2 (en)
BE2013C036I2 (en)
BE2011C030I2 (en)
JP2004209096A5 (en)
BE2013C034I2 (en)
JP2003260696A5 (en)
JP2003338636A5 (en)
BE2012C053I2 (en)
JP2004027473A5 (en)
DE502004010578D1 (en)
JP2004003470A5 (en)
JP2004183660A5 (en)
JP2004046092A5 (en)
JP2004004921A5 (en)
JP2004216063A5 (en)
AU2002310561A1 (en)
AU2002331433A1 (en)
AU2002255066A1 (en)
AU2002256398A1 (en)
AU2002327042A1 (en)
AU2002254584A1 (en)
FR2835198A3 (en)